Loading
A phase 1 trial of ELVN-002 run by Enliven Therapeutics, active and no longer recruiting.
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer is a phase 1 interventional study registered as NCT06328738 by Enliven Therapeutics, with 275 participants planned, started 2024-05-30. Conditions recorded: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification and Colorectal Cancer. Interventions recorded: ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel and Leucovorin.
Shares ELVN-002, Enliven Therapeutics, HER2-positive breast cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2-positive gastric cancer, HER2-positive breast cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2-positive gastric cancer, HER2-positive breast cancer and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares Enliven Therapeutics and the tag pipeline.
Shares HER2-positive gastric cancer and the tag pipeline.
Shares HER2-positive gastric cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/